Edwards Lifesciences Corp. and Medtronic Inc. rose in New York trading after studies were released that will increase use of their man-made valves that can be inserted into the heart without cracking open the chest.
Weight-loss surgery may be a better way to treat diabetes than traditional drug therapy alone, according to a study that found the operation was more likely to keep the chronic condition at bay for at least three years.
Patients with mild heart failure live longer if they’re treated with advanced defibrillators that synchronize the beating of the heart in addition to shocking it back into rhythm when it stops, a study found.
The battle for control of a developing market for heart valves that can be inserted without open-heart surgery intensified today as Edwards Lifesciences Corp.’s second-generation product was found to outperform Medtronic Inc.’s device in a head-to-head comparison.
Medtronic Inc.’s man-made aortic valve, inserted into the heart without cracking open the chest, reduced patient death rates more than open-heart surgery in the first study to ever record such a finding.
Medtronic Inc. isn’t giving up on a new approach to treat hypertension with a device designed to sear the nerves that spur high blood pressure, even though the first rigorous trial of the method failed to help patients, company officials said.